Patent ID: 11897948
Assignee: AVEO PHARMACEUTICALS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method of decreasing blood urea nitrogen (BUN) levels in a subject with hyperuricemia, the method comprising administering an effective amount of an anti-GDF15 antibody that decreases or inhibits GDF15 activity in the subject, wherein the anti-GDF15 antibody is selected from:
a) an antibody comprising the heavy chain sequence of SEQ ID NO:47 or 49 and the light chain sequence of SEQ ID NO:30;
b) an antibody comprising the heavy chain sequence of SEQ ID NO:41, 42, 43, 44, 45, 46, 48, or 49 and the light chain sequence of SEQ ID NO:29;
c) an antibody comprising the heavy chain sequence of SEQ ID NO:41, 42, 43, 44, or 45 and the light chain sequence of SEQ ID NO:28;
d) an antibody comprising the heavy chain sequence of SEQ ID NO:39, 40, 41, 42, 43, 44, or 45 and the light chain sequence of SEQ ID NO:27;
e) an antibody comprising the heavy chain sequence of SEQ ID NO:38 and the light chain sequence of SEQ ID NO:26;
f) an antibody comprising the heavy chain sequence of SEQ ID NO:37 and the light chain sequence of SEQ ID NO:25;
g) an antibody comprising a heavy chain CDRH1 sequence of SEQ ID NO:1, a heavy chain CDRH2 sequence of SEQ ID NO:7, and a heavy chain CDRH3 sequence of SEQ ID NO:13; and
a light chain CDRL1 sequence of SEQ ID NO:16, a light chain CDRL2 sequence of SEQ ID NO:18, and a light chain CDRL3 sequence of SEQ ID NO:22;

h) an antibody comprising a heavy chain CDRH1 sequence of SEQ ID NO:1, a heavy chain CDRH2 sequence of SEQ ID NO:9, and a heavy chain CDRH3 sequence of SEQ ID NO:13; and
a light chain CDRL1 sequence of SEQ ID NO:16, a light chain CDRL2 sequence of SEQ ID NO:18, and a light chain CDRL3 sequence of SEQ ID NO:22;

i) an antibody comprising a heavy chain CDRH1 sequence of SEQ ID NO:1, a heavy chain CDRH2 sequence of SEQ ID NO:4, and a heavy chain CDRH3 sequence of SEQ ID NO:13; and
a light chain CDRL1 sequence of SEQ ID NO:16, a light chain CDRL2 sequence of SEQ ID NO:18, and a light chain CDRL3 sequence of SEQ ID NO:21;

j) an antibody comprising a heavy chain CDRH1 sequence of SEQ ID NO:1, a heavy chain CDRH2 sequence of SEQ ID NO:5, and a heavy chain CDRH3 sequence of SEQ ID NO:13; and
a light chain CDRL1 sequence of SEQ ID NO:16, a light chain CDRL2 sequence of SEQ ID NO:18, and a light chain CDRL3 sequence of SEQ ID NO:21;

k) an antibody comprising a heavy chain CDRH1 sequence of SEQ ID NO:1, a heavy chain CDRH2 sequence of SEQ ID NO:6, and a heavy chain CDRH3 sequence of SEQ ID NO:13; and
a light chain CDRL1 sequence of SEQ ID NO:16, a light chain CDRL2 sequence of SEQ ID NO:18, and a light chain CDRL3 sequence of SEQ ID NO:21;

l) an antibody comprising a heavy chain CDRH1 sequence of SEQ ID NO:1, a heavy chain CDRH2 sequence of SEQ ID NO:8, and a heavy chain CDRH3 sequence of SEQ ID NO:13; and
a light chain CDRL1 sequence of SEQ ID NO:16, a light chain CDRL2 sequence of SEQ ID NO:18, and a light chain CDRL3 sequence of SEQ ID NO:21; and

m) an antibody comprising a heavy chain CDRH1 sequence of SEQ ID NO:1, a heavy chain CDRH2 sequence of SEQ ID NO:9, and a heavy chain CDRH3 sequence of SEQ ID NO:13; and
a light chain CDRL1 sequence of SEQ ID NO:16, a light chain CDRL2 sequence of SEQ ID NO:18, and a light chain CDRL3 sequence of SEQ ID NO:21.